Dear Sir, In uremia, an imbalance in the prostaglandin (PG) system, and altered platelet function are well known. A number of disturbances in the PG system related to PGL·, such as increased plasma factor activity [1], and prolonged [2] as well as increased [3] formation of PGL· by the vessel wall have been described. In vivo, PGL· is bound to proteins and thereby stabilized. So far, a shortened PGL· half-life (t½) has been described in thrombotic thrombocytopenic purpura [4], indicating impaired stabilization due to decreased protein binding, as well as after myocardial infarction [5, 6] and -with an extremely low prevalence -in healthy adults [7]. We report for the first time an extreme prolongation in the degradation half-life of the biologically active PGL· in vitro due to unknown reason. It is assumed that this defect leading to the prolonged local availability of PGL· at higher amounts might have contributed to the clinically manifest bleeding observed in our patient. A 65-year-old male patient on long-term hemodialysis for 13 years was hospitalized due to severe epistaxis, occult blood loss in stool, and chest pains. At hospital admission, blood pressure (115/50), heart rate (80/min), and plasmatic coagulation parameters (PTT, fibrinogen) were normal. The platelet count was extremely decreased (2,000/µl), normochromic anemia was present; the semi-quantitative evaluation of bone marrow aspiration showed a normal ratio of granulo-to erythropoiesis beside a significantly decreased megakaryopoiesis. In serum, neither antibodies against rhesus factor nor HR antibodies were found; the platelet immune fluorescence antibody test was negative. Due to the extremely low platelet count, further extensive platelet function testing was not possible. Table 1 . PGI2 degradation (t½) and PF in the patient compared to a healthy control During hospitalization, the patient received transfusions as well as platelet concentrates and fresh frozen plasma. Beside his standard therapy, he underwent treatment with 7S immunoglobulins, corticosteroids, danazole, and vincristine. PGL· t½ was measured with a bioassay, and measurements of PGL· synthesis stimulating plasma factor (PF) were performed using a bioassay compared to a radioimmunoassay (RIA). Our patient showed an extreme prolongation in the in vitro degradation half-life of the biologically active PGL· to 108 min (table 1), the normal values under the same assay conditions
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